Literature DB >> 6187581

Differential expression of HLA-DR and DR-linked determinants on human leukemias and lymphoid cells.

R A Newman, D Delia, M F Greaves, C Navarrete, L Fainboim, H Festenstein.   

Abstract

Leukemic and normal hemopoietic cells were examined with the monoclonal anti-bodies DA2 and Genox 353 for the presence of HLA-DR and DR-linked (DC/MB) determinants, respectively. Although most non-T acute leukemias and leukemic cell lines expressed the monomorphic DR determinant detected by DA2, fewer than expected expressed the DR-linked polymorphic specificity detected by Genox 353. TdT+ lymphoid precursors from normal bone marrow were also DA2+ but Genox 353-. T cells and thymocytes which were DA2-, Genox 353- became DA2+, Genox 353+ after activation in vitro. Immunoprecipitation using DA2 and Genox 353 gave bands on polyacrylamide gel-electrophoresis which were of different molecular weights. In addition, DA2 could absorb out Genox 353 determinants from a cell lysate whereas Genox 353 could not absorb out DA2 determinants. It is concluded that DA2 and Genox 353 detect HLA-DR and DR-linked (DC1/MB1) determinants, respectively, and that these are differentially expressed on hemopoietic cells during differentiation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6187581     DOI: 10.1002/eji.1830130215

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

1.  Interpretation of the specificities of monoclonal antibodies recognising human MHC class II antigens.

Authors:  K Guy; C M Steel
Journal:  Clin Exp Immunol       Date:  1985-01       Impact factor: 4.330

2.  MHC class II antigen and immunoglobulin expression in spontaneous phenotypic variants of the Burkitt's lymphoma cell line Namalwa.

Authors:  K Guy; P G Middleton; L J Docherty; C L De Angelis; C M Steel
Journal:  Immunology       Date:  1986-12       Impact factor: 7.397

3.  Detection of the common acute lymphoblastic leukaemia antigen (CALLA) on B cells from human fetal tissues. A multiple phenotypic characterization.

Authors:  D Delia; G Cattoretti; A Bonati; S Villa; F De Braud; M Buscaglia
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

4.  B cells from chronic lymphocytic leukemia (CLL) patients are strong inducers of proliferation and major histocompatibility complex (MHC)-unrestricted [natural killer (NK)-like] cytotoxicity in normal T-lymphocytes.

Authors:  L Matera; R Foa; M Massaia; M Giovarelli; F Veglia; A Cesano; P Lusso; A Piazza; D Santoli
Journal:  J Clin Immunol       Date:  1989-07       Impact factor: 8.317

5.  Differential expression of HLA class II antigens on human fetal and adult lymphocytes and macrophages.

Authors:  J A Edwards; D B Jones; P R Evans; J L Smith
Journal:  Immunology       Date:  1985-07       Impact factor: 7.397

Review 6.  The HLA system: structure and function.

Authors:  W F Bodmer
Journal:  J Clin Pathol       Date:  1987-09       Impact factor: 3.411

7.  Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens.

Authors:  P G Natali; O Segatto; S Ferrone; R Tosi; G Corte
Journal:  Immunogenetics       Date:  1984       Impact factor: 2.846

8.  HLA-DR expression is associated with excellent prognosis in squamous cell carcinoma of the larynx.

Authors:  F Esteban; F Ruiz-Cabello; A Concha; M Pérez-Ayala; J A Sánchez-Rozas; F Garrido
Journal:  Clin Exp Metastasis       Date:  1990 Jul-Aug       Impact factor: 5.150

9.  Expression of MHC class II antigens in human B-cell leukaemia, and increased levels of class II antigens and DR-specific mRNA after stimulation with 12-O-tetradecanoyl phorbol-13-acetate.

Authors:  K Guy; R R Meehan; A E Dewar; D Larhammar
Journal:  Immunology       Date:  1986-02       Impact factor: 7.397

10.  An HLA-DR negative acute leukaemia which stimulates MLC and CMC responses.

Authors:  G M Taylor; W Fergusson; P A Dyer; R Harris; G Morrell
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.